Deal Flow
Letter · prints on one page
Transaction tear sheetData as of Nov 7, 2026
M&A · Healthcare · Electromedical & Electrotherapeutic Apparatus

Management Group led by Timothy Damadian to acquire Fonar Corp

Announced Dec 29, 2025 · Closed Jun 3, 2026

Deal value—
Premium31.5%To unaffected price
EV / Adj. EBITDA—
ConsiderationAll cash$19.00 per share

Transaction

Acquirer
Management Group led by Timothy Damadian
Target
Fonar Corp (FONR)
Buyer type
Strategic
Offer price per share
$19.00
Enterprise value
—
Status
Closed Jun 3, 2026

Deal protections

Break fee (target pays)
$0.5M
Reverse fee (buyer pays)
—
Go-shop
No-shop
Financing
No financing condition

Advisors

To the acquirer
Not disclosed
To the target
Not disclosed

Sector context · Healthcare

Comparable deals
97 in the prior 24 months
Premium
31.5% vs. 59.0% sector median
EV / Adj. EBITDA
Sector median 14.5x
Break fee
Sector median 3.4%

Timeline

  1. AnnouncedDec 29, 2025
  2. Proxy filedFeb 26, 2026
  3. Definitive proxyApr 16, 2026
  4. Shareholder voteMay 28, 2026
  5. ClosedJun 3, 2026

Valuation · fairness opinions

Other analysis$10.32$11.06
Offer $19.00

Implied value per Fonar Corp share by analysis.

Sources
  • 8-K (EX-99) · Dec 30, 2025
  • DEFA14A (EX-99) · Dec 30, 2025

Adj. EBITDA is operating income + D&A + impairment, restructuring, deal costs and stock compensation, less any large gain on a sale, last twelve months, from the target's filings. Calculated by Castle, so it can differ from a bank's adjusted figure.

Prepared with Castle from public SEC EDGAR filings. Figures are extracted automatically; verify against the source documents. Not investment advice.